BCG vaccine SSI

BIOLOGICAL3 trials

Sponsors

Mark Hatherill, Radboud University Medical Center, Gates Medical Research Institute

Conditions

HIVInnate Immune ResponseTuberculosis

Phase 2

Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination

CompletedNCT01650389

Mark HatherillHIV, Tuberculosis

Start: 2012-10-31End: 2015-05-31Updated: 2015-09-30

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

TerminatedNCT04152161

Gates Medical Research InstituteTuberculosis

Start: 2019-10-16End: 2024-05-14Updated: 2025-06-19

Unknown Phase

γ-irradiated BCG to Train Innate Immunity

CompletedNCT02259608

Radboud University Medical CenterInnate Immune Response

Start: 2013-11-30End: 2014-04-30Updated: 2016-06-29

Related Papers

BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> Infection

New England Journal of Medicine2025-05-0723 citations

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial

Clinical Infectious Diseases2017-09-2235 citations